Will Third Time Be Charm For Lovenox Patent Re-issuance? Aventis Considers Options
This article was originally published in The Pink Sheet Daily
Executive Summary
Aventis will continue to pursue re-issuance of its '618 Lovenox patent despite a second rejection letter from the Patent & Trademark Office. The firm has not decided whether to appeal the decision or present further evidence.
You may also be interested in...
Lovenox Patent Could Be Reissued In Mid-2005, Sanofi-Aventis Says
Patent & Trademark Office allows Sanofi-Aventis’ reissuance application after twice rejecting the request. The company says reissuance of the ’618 patent, which expires in 2012, will bolster its position in litigation against enoxaparin ANDA filers.
Lovenox Patent Could Be Reissued In Mid-2005, Sanofi-Aventis Says
Patent & Trademark Office allows Sanofi-Aventis’ reissuance application after twice rejecting the request. The company says reissuance of the ’618 patent, which expires in 2012, will bolster its position in litigation against enoxaparin ANDA filers.
GSK Requesting Re-Issuance Of Advair Patent
GlaxoSmithKline will apply to the Patent & Trademark Office for re-issuance of an Advair patent that expires in September 2010, the company's second quarter earnings release says